Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Raised by Golden State Wealth Management LLC

Golden State Wealth Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 123.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,940 shares of the medical research company's stock after purchasing an additional 2,173 shares during the quarter. Golden State Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $1,961,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cypress Advisory Group LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at $253,000. Intact Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after purchasing an additional 660 shares during the period. Purkiss Capital Advisors LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $1,121,000. LaFleur & Godfrey LLC boosted its holdings in Thermo Fisher Scientific by 9.1% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after purchasing an additional 2,488 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after buying an additional 114,277 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.3%

Shares of TMO stock traded up $1.37 on Thursday, hitting $412.02. The stock had a trading volume of 2,926,073 shares, compared to its average volume of 1,958,976. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The firm has a market capitalization of $155.53 billion, a price-to-earnings ratio of 24.17, a P/E/G ratio of 2.17 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The stock's 50 day moving average is $410.39 and its 200-day moving average is $485.33.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the firm earned $5.11 earnings per share. The company's revenue was up .2% on a year-over-year basis. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Finally, Scotiabank lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $604.05.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.